Shots:

• The P-III SURPASS-CVOT study involves assessing non-inferiority and superiority of tirzepatide vs Trulicity (dulaglutide- 15mg) in 12-500 patients with T2D and atherosclerotic cardiovascular disease from 30 countries. The company expects for the completion of trial in four years
• The 1EPs will measure time to first occurrence of MACE-3- the composite endpoint of CV death- myocardial infarction- or stroke while the 2EPs is time to all-cause mortality and time to occurrence of each component of the primary endpoint
• Trulicity (dulaglutide) is an injectable prescribed medicine for T2D patients used to improve blood sugar (glucose) and used to reduce the risk of major cardiovascular events such as death- heart attack- or stroke in people who have heart disease or multiple cardiovascular risk factors

Click here to read full press release/ article 

 Ref: PRNewswire | Image: Eli Lilly